Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Domperidone, a dopamine antagonist metabolized mainly by CYP3A, has been used as an anti‐emetic and prokinetic agent by mouth for over 30 years.• Domperidone has a good safety record. However, early studies of high dose intravenous domperidone were associated with QTcprolongation and arrhythmias, including torsade de pointes.• There have been no thorough QTcstudies of domperidone.WHAT THIS STUDY ADDS• We assessed the effect on QTcof oral domperidone and ketoconazole, alone and in combination.• •Ketoconazole, a CYP3A inhibitor, tripled domperidone concentrations, whilst domperidone did not affect ketoconazole concentrations.• •Domperidone and ketoconazole, alone and in combination, increased QTcsignificantly in men, and there was a positive correlation between increased QTcand concentrations of domperidone and ketoconazole in both sexes.• The effect of domperidone alone on QTcwas small and not clinically important, but domperidone should not be co‐administered with ketoconazole.AIMSTo assess the steady‐state pharmacokinetic and QTceffects of domperidone and ketoconazole, given alone and together.METHODSA randomized, placebo‐controlled, double‐blind, crossover study was carried out. Healthy subjects (14 men, 10 women; age 18–39 years; mean weight 73.5 kg, range 53.8–98.8 kg; 23 Europid, 1 Afro‐Caribbean) received orally, for 7 days each, placebo, domperidone 10 mg, four doses daily, at 4 h intervals, ketoconazole 200 mg 12‐hourly and domperidone and ketoconazole together. The washout period was 15 days. Pharmacokinetics and serial 12‐lead ECGs were assessed on day 7, and serial ECGs on day −1 and at follow‐up. Two subjects withdrew before the third treatment period, so data were available for 22–24 subjects.RESULTSKetoconazole tripled domperidone concentrations at steady‐state. Domperidone, ketoconazole and their combination significantly increased QTcF in men. Overall adjusted mean differences from placebo were 4.20 (95% CI 0.77, 7.63), 9.24 (95% CI 5.85, 12.63) and 15.90 (95% CI 12.47, 19.33) ms, respectively. In women, QTcF was not significantly different from placebo on either domperidone or ketoconazole alone, or in combination. However, QTcwas positively correlated with plasma drug concentrations, in both men and women. ΔQTcF increased by about 2 ms per 10 ng ml–1rise in domperidone concentration, and per 1 µg ml–1rise in ketoconazole concentration.CONCLUSIONSKetoconazole tripled the plasma concentrations of domperidone. Domperidone and ketoconazole increased QTcF in men, whether given together or separately. The effect of domperidone alone was below the level of clinical importance. The negative result in women is unexplained.

This publication has 30 references indexed in Scilit: